SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium

Jonathan E.M. O'Donnell, Lucy A. Hastings, Julie N. Briody, Christine L. Chan, Carla Colombo, Tonia A. Douglas, Steven D. Freedman, Tanja Gonska, Jerry R. Greenfield, Daniel H. Leung, Adeline Y.L. Lim, Antoinette Moran, Bernadette J. Prentice, Melissa S. Putman, Michael Trotter, Elizabeth Tullis, Glen P. Westall, Charles F. Verge, Claire E. Wainwright, Chee Y. OoiJohn F. Engelhardt, Tamarah Katz, Susannah King, Peter J. Lewindon, Angela G. Matson, Catherine M. McDonald, Amir Moheet, Michael R. Narkewicz, Mark Oliver, Grant A. Ramm, Zachary M. Sellers, Michael Wilschanski

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Cystic fibrosis (CF) is a life-shortening multisystem genetic disease. Although progressive pulmonary disease is the predominant cause of morbidity and mortality, improvements in treatment for CF-related lung disease, with associated increase in longevity, have increased the prevalence of extrapulmonary manifestations1. Methods: To discuss these issues, a multidisciplinary meeting of international leaders and experts in the field was convened in November 2021 at the Shaping Initiatives and Future Trends Symposium with the goal of highlighting shifting management paradigms in CF. The main topics covered were: (1) nutrition and obesity, (2) exocrine pancreas, (3) CF-related diabetes, (4) CF liver disease, (5) CF-related bone disease, and (6) post-lung transplant care. This document summarizes the proceedings, highlighting the key priorities and important research questions that were discussed. Results: Improved life expectancy, the advent of cystic fibrosis transmembrane conductance regulator modulators, and the increasing appreciation of the heterogeneity or spectrum of disease are leading to a shift in management for patients with cystic fibrosis. Care should be individualized to ensure that increased longevity is accompanied by improved extra-pulmonary care and reduced morbidity.

Original languageEnglish (US)
Pages (from-to)1661-1676
Number of pages16
JournalPediatric pulmonology
Volume59
Issue number6
DOIs
StatePublished - Jun 2024

Bibliographical note

Publisher Copyright:
© 2024 The Authors. Pediatric Pulmonology published by Wiley Periodicals LLC.

Keywords

  • cystic fibrosis
  • cystic fibrosis bone disease
  • cystic fibrosis related diabetes
  • cystic fibrosis related liver disease
  • exocrine pancreatic disease
  • extra-pulmonary complications cystic fibrosis
  • lung transplant
  • nutrition

Fingerprint

Dive into the research topics of 'SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium'. Together they form a unique fingerprint.

Cite this